Program advances to lead compound evaluation
in preclinical in vivo models
Preliminary data for in vivo studies are
expected in second half of 2023
SAN
DIEGO, June 20, 2023 /PRNewswire/ -- Regulus
Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
an update on its preclinical studies evaluating a library of
oligonucleotides designed to inhibit miR-155 for the treatment of
Amyotrophic Lateral Sclerosis (ALS, or Lou
Gehrig's disease). Regulus is pursuing this effort in
collaboration with the laboratories of Oleg
Butovsky, Ph.D., and Howard L.
Weiner, M.D., at Brigham and Women's Hospital (BWH) and the
Foundation for Neurologic Diseases (Boston, MA). The early-stage collaboration
began in September 2021, and has now
advanced to evaluation of compounds of interest in ALS preclinical
in vivo models.
This milestone follows the successful completion of an
oligonucleotide library and microglia cell-based screening campaign
which identified compelling inhibitors of miR-155. Regulus
and BWH are now evaluating the pharmacologic effects of selected
anti-miR-155 inhibitors in preclinical ALS animal models, with an
ultimate goal of achieving therapeutic efficacy and clinical
translation for ALS patients. Preliminary data for these in vivo
preclinical studies are expected in the second half of 2023.
"We are very excited about the latest progress in our productive
partnership with Drs. Butovsky and Weiner at BWH, which brings us
one step closer to translating our preclinical research into a
potentially meaningful treatment for patients with ALS, a
devastating disease of the central nervous system," said
Jay Hagan, President and Chief
Executive Officer of Regulus Therapeutics. "We look forward to
reviewing preliminary data later this year, and to further explore
the impact of our anti-miR-155 inhibitors in this devastating
neurologic disease."
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate headquarters in
San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements associated with the Company's
preclinical programs, including the expected timing for initiating
studies, the expected timing for reporting topline data, and the
timing and future occurrence of other preclinical and clinical
activities. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and the risk additional
toxicology data may be negative. In addition, while Regulus expects
the COVID-19 pandemic to adversely affect its business operations
and financial results, the extent of the impact on Regulus' ability
to achieve its preclinical and clinical development objectives and
the value of and market for its common stock, will depend on future
developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the
pandemic, travel restrictions, quarantines, social distancing and
business closure requirements in the U.S. and in other countries,
and the effectiveness of actions taken globally to contain and
treat the disease. These and other risks are described in
additional detail in Regulus' filings with the Securities and
Exchange Commission, including under the "Risk Factors" heading of
Regulus' most recently filed annual report on Form 10-Q. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Regulus undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-update-on-preclinical-studies-in-amyotrophic-lateral-sclerosis-in-collaboration-with-researchers-from-harvards-brigham-and-womens-hospital-301855288.html
SOURCE Regulus Therapeutics Inc.